Open AccessPseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report
Author(s) -
Trabjerg Natacha Dencker,
Rask Christina,
Jensen Lars Henrik,
Hansen Torben Frøstrup
Publication year - 2019
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.2262
Subject(s) - medicine , pembrolizumab , carcinoembryonic antigen , immunotherapy , colorectal cancer , chemotherapy , oncology , cancer , disease
Disease progression during immunotherapy in colorectal cancer does not always indicate treatment failure. A case argues that carcinoembryonic antigen (CEA) may serve as an early marker to distinguish between pseudoprogression and real progression. Presentation of results from reintroduction of chemotherapy after progression on immunotherapy that suggest increased efficiency.